Prognostic impact of telomere maintenance gene polymorphisms in hepatocellular carcinoma patients: Some issues need to be clarified
Fei Liu, Wen‐Tao Wang, Yong‐Gang Wei, Bo Li – 20 April 2014
Reply
Neung Hwa Park, Seok Won Jung, Eun‐Soon Shin, Young‐Hwa Chung – 20 April 2014
Association between response to pegylated interferon/ribavirin therapy and ribavirin levels
Chia‐Yen Dai, Ming‐Lung Yu, Wan‐Long Chuang – 19 April 2014
Reply
Riad Salem, Michael Vouche, Ali Habib, Edward Kim, Kent T. Sato, Ryan Hickey, Robert Lewandowski – 19 April 2014
Iron‐induced oxidative rat liver injury after non–heart‐beating warm ischemia is mediated by tumor necrosis factor α and prevented by deferoxamine
Xianwa Niu, Wen Hua Huang, Bastiaan De Boer, Luc Delriviere, Ling Jun Mou, Gary P. Jeffrey – 19 April 2014 – This study investigated iron‐induced injury after warm ischemia in a non–heart‐beating (NHB) rat liver model and the effects of deferoxamine (DFO). Livers from heart‐beating (HB) rats or rats that were NHB for 60 minutes were stored in University of Wisconsin solution for 5 hours at 4°C [cold storage (CS)] and then were subjected to 2 hours of machine reperfusion (MRP) at 37°C.
Persistent viremia in human immunodeficiency virus/hepatitis B coinfected patients undergoing long‐term tenofovir: Virological and clinical implications
Anders Boyd, Joël Gozlan, Sarah Maylin, Constance Delaugerre, Gilles Peytavin, Pierre‐Marie Girard, Fabien Zoulim, Karine Lacombe – 19 April 2014 – Tenofovir (TDF) is considered the ideal treatment for patients coinfected with human immunodeficiency virus (HIV) and hepatitis B virus (HBV). However, certain coinfected patients exhibit incomplete viral suppression, with persistent, and sometimes transient, bouts of HBV replication. The reasons for this, including clinical effect, are unclear.
Ursodeoxycholic acid in primary sclerosing cholangitis: If withdrawal is bad, then administration is good (right?)
James H. Tabibian, Keith D. Lindor – 19 April 2014
Vitamin D deficiency and liver cancer: More than just an epidemiological association?
Massimo Colombo, Angelo Sangiovanni – 19 April 2014
Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease
Pierre Bedossa, the FLIP Pathology Consortium – 19 April 2014 – Biopsy is still the gold standard for the diagnosis of nonalcoholic steatohepatitis but the definition may vary among pathologists, a drawback especially in evaluation of biopsies for clinical trials. We previously developed a scoring system (steatosis, activity, fibrosis [SAF]) allowing the use of an algorithm (fatty liver inhibition of progression [FLIP]) for the classification of liver injury in morbid obesity.
Hepatocyte nuclear factor 4α‐nuclear factor‐κB feedback circuit modulates liver cancer progression
Bei‐Fang Ning, Jin Ding, Jiao Liu, Chuan Yin, Wen‐Ping Xu, Wen‐Ming Cong, Qing Zhang, Fei Chen, Tao Han, Xing Deng, Pei‐Qin Wang, Cai‐Feng Jiang, Jun‐Ping Zhang, Xin Zhang, Hong‐Yang Wang, Wei‐Fen Xie – 18 April 2014 – Hepatocyte nuclear factor 4α (HNF4α) is a liver enriched transcription factor and is indispensable for liver development. However, the role of HNF4α in hepatocellular carcinoma (HCC) progression remains to be elucidated.